Enveric Biosciences Reports Favorable EB-003 Data
The drug candidate shows promising metabolic stability as it targets receptors for psychiatric and neurological conditions.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize long-term safety over fast-acting medical results?
Enveric Biosciences has reported favorable preclinical laboratory results for its drug candidate EB-003. This research-stage molecule is designed to treat psychiatric and neurological conditions without inducing hallucinogenic effects.
Why it matters
The company is seeking to expand the therapeutic utility of psychedelics-inspired medicine by decoupling their psychiatric benefits from the hallucinogenic reactions typically associated with these compounds.
Enveric Biosciences evaluated EB-003 across 70 individual assays, finding potential for intestinal absorption and stability against liver enzymes. The data also suggests low plasma protein binding and minimal inhibition of primary metabolic enzymes.
The players
Enveric Biosciences
A biotechnology company focused on developing small-molecule therapeutics for psychiatric and neurological disorders using psychedelic-inspired drug discovery.
The details
Researchers engineered EB-003 to target 5-HT2A and 5-HT1B receptors, which are proteins on the surface of neurons that mediate various neurotransmitter signals. By modulating these specific receptor sites, the company aims to produce therapeutic effects for neurological conditions. The molecule was tested to ensure it remains stable during metabolism and does not interfere with standard transporter proteins in the liver.
Timeline
October 21, 2026: Enveric Biosciences reported preclinical results for EB-003.
The Tech Race
This development sits within the broader, active research program into the development of non-hallucinogenic psychedelics as an alternative to traditional compounds. Enveric Biosciences is positioning EB-003 as a viable candidate to test whether psychiatric benefits can be isolated from perceptual side effects.
As this candidate is currently in the research stage, it is not yet available for clinical or medical use. The company plans to advance the molecule toward first-in-human clinical trials to further assess its viability for treating psychiatric conditions.
The takeaway
The next milestone for EB-003 is the transition to first-in-human clinical trials. Stakeholders should track these upcoming trial applications to determine if the molecule maintains its lab-demonstrated safety and absorption profile in a biological system.
Further reading
For broader trends in psychiatric drug discovery, explore the Biotech section.
Live Poll
Do you trust pharmaceutical companies to prioritize long-term safety over fast-acting medical results?
